Number randomized 35,533

8,856 assigned to Placebo
155 removed from 2 poor performing sites
1 prior prostate cancer
4 randomized in error
8,696 included in all analysis
133 Clinically ineligible
154 Insuff. baseline data
420 Lost to follow-up

8,904 assigned to Vitamin E
156 removed from 2 poor performing sites
5 prior prostate cancer
6 randomized in error
8,737 included in all analysis
128 Clinically ineligible
151 Insuff. baseline data
385 Lost to follow-up

8,910 assigned to Selenium
155 removed from 2 poor performing sites
1 prior prostate cancer
2 randomized in error
8,752 included in all analysis
113 Clinically ineligible
166 Insuff. baseline data
434 Lost to follow-up

8,863 assigned to Combination
155 removed from 2 poor performing sites
2 prior prostate cancer
3 randomized in error
8,703 included in all analysis
113 Clinically ineligible
169 Insuff. baseline data
379 Lost to follow-up

1: All participants from 2 sites removed due to poor data participant management, data management, and regulatory issues.
2: Proper informed consent never received.
3: Clinically ineligible due to elevated blood pressure, high grade PIN, suspicious DRE or elevated PSA, aspirin dosage, prior cancer < 5 years prior to randomization, participation in another clinical trial or other clinical reason. These men were included in all analyses.
4: Insufficient baseline data to completely evaluate clinical eligibility. Blood pressure, PSA and/or DRE not done within required time frame (but normal) or other data-related reason. These men were included in all analyses.
5: Last contact date > 24 months prior to analysis. All data up until their last contact are included in all analyses. For time-to-event analyses, these men are censored at their last follow-up. These men could also have been either clinically ineligible or had insufficient baseline data.